20th-22nd February 2017, **Berlin**

Register Now to Save €500

7th ANNUAL WORLD adc BERLIN

> "Excellent conference. We have made good progress in ADC's but only scratched the surface of our knowledge of them"
> Seattle Genetics

Improve Safety & Efficacy of Your Antibody Drug Conjugate Programme to Meet Patient Needs

Attend this year's Summit to:

- Design next generation ADCs
- Effectively translate into the clinic
- Expand clinical therapeutic index
- Advance clinical scale manufacturing

300+ attendees | **120 organisations**

55 sessions to participate in

New Analytical & Bioanalytical Day

49 expert speakers

49 industry expert speakers, including:

Tony Cano
Senior Director
Stemcentrx-AbbVie

Dhaval Shah
Assistant Professor
University of Buffalo

Wayne Widdison
Associate Director
ImmunoGen

Iontcho Vlahov
Vice President
Endocyte

Steve Coats
Vice President
MedImmune

Ron Lin
Founder & CEO
AbGenomics

Senior Partners:

MilliporeSigma

Levena Biopharma

To find out more visit: **www.worldadc-europe.com**

Tel: +44 (0) 203 141 8700 | **Email:** adc@hansonwade.com @World_ADC #WorldADC Antibody Drug Conjugates

hansonwade
love what you do

Welcome to **7th Annual World ADC Berlin**

Maximise the Clinical Therapeutic Window of your ADC

World ADC Berlin is Europe's longest running and most detailed antibody-drug conjugate conference.

Each year, over **300 of your peers unite at this industry focused summit** to immerse themselves in cutting-edge ADC science. Across 3 days, this comprehensive 3 streamed programme covers every element of ADCs from discovery, development, manufacturing and clinical.

At the 7th World ADC, **49 industry experts will present ground-breaking scientifically novel ADC research** on warheads with differentiated mechanism of action, tools for improving interpretation of PK data, more robust clinical dosing strategies and processes for scaling up bio-conjugation.

Designed for you, World ADC will give you an unparalleled depth of insight making it your definitive ADC conference for 2017.

Join your peers next February at World ADC to gain cutting-edge insight, data and lessons learned to **power the next 12 months of your antibody drug conjugate research.**

Don't miss this opportunity to **build on existing connections and foster new partnerships.**

Hear What Previous Attendees Have To Say:

"Very informative, focused conference on all aspects of ADC research and development"

Bayer

"The speakers truly love what they do and it resonated in their presentations"

Regeneron

"Reports from the early clinical trials indicate that ADCs are setting the bar very high for eliminating cancer and the conference emphasised this exciting development"

Eisai

10 Reasons to Attend World ADC

- Explore payloads with differentiated mechanisms of action for **enhanced efficacy** & **overcome cancer resistance**
- **Minimise off target toxicities** through antibody optimisation & alternative protein formats
- Improve your understanding of the **impact of drug loading on biological activity** of your ADC
- **File a successful IND** by effective characterisation of your ADC molecule and build a robust bioanalytical package
- **Develop scalable, reproducible** & **safe processes** with improved knowledge of process understanding
- Explore novel linker & site specific conjugation technologies which **improve drug stability *in vivo*** and **intracellular localisation of payload in tumour cell**
- Optimise clinical dosing regimes to **minimise severe adverse events** and **cumulative toxicity**
- Improve understanding of how single use technologies can **reduce upfront capital costs of ADC manufacturing**
- Overcome challenges of limited capacities & technical expertise and **robustly outsource your ADC manufacturing** to your chosen CMO
- Learn how to implement a novel model to **quantify the bystander of your ADC *in silico***

Tel: +44 (0)203 141 8700 **Email:** adc@hansonwade.com
www.worldadc-europe.com @World_ADC #WorldADC Antibody Drug Conjugates

What's New for 2017

Empower your ADC drug development with new industry intelligence

Attend World ADC 2017 to **access the latest insight gleaned from clinical development and accelerate your preclinical candidate development**.

Designed for you, based on extensive research with the ADC community, this programme will bring you the latest ADC research and science. Every talk on the World ADC programme will distill **new data, insight** or **lessons learned**.

Here are 5 talks you cannot afford to miss:

- Explore the advantages and disadvantages of single vs. dual payload ADCs *in vitro* and *in vivo* models of cancer with **The Scripps Institute**
- Improve linker stability and clearance rate by evaluating **ImmunoGen's** novel peptide linked maytansinoid ADCs
- Learn the latest advancements in design and development of non-internalising ADCs with **Philochem**
- Effectively translate into the clinic by hearing insight on the preclinical development of **AbGenomics** novel ADC, AbGn-107
- Discover and validate novel targets by gaining lessons learned from LAMP1 with **Sanofi**

"This conference is an unique opportunity to talk about ADCs deeply. It was really fruitful"

Daiichi Sankyo

New Analytical & Bioanalytical Day

Analysis and bioanalysis of ADCs is a rapidly evolving area in preclinical drug development. Yet, the diversity of novel ADC technologies and lack of standardised industry consensus means it is one of the most challenging.

Capturing lessons-learned and distilling the latest industry intelligence **this pre-conference day will enable you to robustly characterise your ADC programme and then tailor for bioanalytical purposes**. Learn how to confidently develop a bioanalytical package and effectively characterise your ADC programme.

Partner & Investor Evening

The successful development of an ADC is reliant on multiple stakeholders working together. Therefore finding the optimal ADC technology, service provider or investor is critical to success.

Taking place at the end of the pre-conference workshop day this social and networking drinks and canapé reception will be the perfect platform for you to meet drug developers, technology developers and service providers in a relaxed atmosphere. **Find the right partner for you at this year's Partnering Evening**.

49 Expert Speakers

Alain Beck
Senior Director
Pierre Fabre

Anette Sommer
Principal Scientist
Bayer

Arnaud Delobel
Scientific Manager
Quality Assistance

Chakrapani Subramanyam
Associate Research Fellow
Pfizer

Charles Dumontet
Team Leader
Cancer Research Centre Lyon

Christoph Rader
Associate Professor
The Scripps Institute

Damon Meyer
Associate Director
Seattle Genetics

David Satijn
Director
Genmab

Dhaval Shah
Assistant Professor
University of Buffalo

Donglu Zhang
Principal Scientist
Genentech

Gary Chen
President
Concortis Biotherapeutics

Guodong Chen
Senior Principal Scientist
Bristol-Myers Squibb

Iontcho Vlahov
Vice President
Endocyte

Joachim Krueger
Head
Bayer

John Lambert
Executive Vice President & Distinguished Research Fellow
ImmunoGen

Judy Hsii
Senior Engineer & Group Leader
Genentech

Kurt Gish
Associate Director II
AbbVie

Ling Xu
Senior Scientist
Takeda

Lucia D'Amico
University Hospital Basel

Maria Elena Guadagno
Director
BSP Pharmaceuticals

Martin Mattarella
Head
Philochem

TBC
Millipore Sigma

Miro Eigemann
Researcher
Roche

Olivier Heudi
Laboratory Head
Novartis

Olivier Marcq
Group Lead
Agensys

Pernille Hemmingsen
Project Manager
Genmab

Puja Sapra
Executive Director
Pfizer

Expert Speakers

Robert Kolakowski
Senior Scientist
Seattle Genetics

Robert Xin
Executive Director & Global Clinical Lead
Pfizer

Ron Lin
Founder & CEO
AbGenomics

Sophia Hober
Professor
KTH

Steve Coats
Vice President
MedImmune

Thomas Wickham
Vice President
Merrimack Pharmaceuticals

Tok Han
Director
Pfizer

Tony Cano
Senior Director
Stemcentrx-AbbVie

Ulf Grawunder
CEO & Founder
NBE Therapeutics

Wayne Widdison
Associate Director
ImmunoGen

Yves Baudat
Scientist
Sanofi

Roberto Depaz
Senior Scientist
MedImmune

Afsaneh Abdolzade-Bavil
Manager
Biotest

Alex Lazar
Head
ImmunoGen

Cong Wei
Senior Scientist
Vertex Pharmaceuticals

Yannis-Nicolas Francois
Assistant Professor
University of Strasbourg

Norbert Sewald
Professor
University of Bielefeld

Christine Sedlik
Researcher
Institut Curie

Ulrich Storz
Senior Partner
Michalski Hüttermann Patent Attorneys

Justin Mason-Home
Managing Director
SafeBridge Consultants

Jonas Helma
Ludwig-Maximilians-University of Munich

Dominik Schumacher
Leibniz-Institute for Molecular Pharmacology

> Again a focused conference. Great to learn about the cutting edge research & development in the ADC space
>
> **Pfizer**

Pre-conference Workshops | Monday 20th February

Workshop A

Exploring Novel Payloads & Their Differentiated Mechanisms of Action

Date: Monday 20th February | Time: 10.00-13.00

This workshop will focus on developing **novel payloads with differentiated mechanisms of action for the optimisation of antibody drug conjugates therapeutic index.**

Join fellow ADC developers at this workshop to learn about:

- The most desirable properties of payloads
- The range of payload types currently available and their MOAs
- The use of molecular modelling approaches to payload discovery
- Designing payloads with maximum cytotoxicity
- Engineering payloads that will not release prematurely
- Designing and developing cryptophycins as next generation payloads for ADCs

Workshop leader
Norbert Sewald, Professor, **University of Bielefeld**

OR

Workshop B

Clinical ADC Development: Maximise the Clinical Therapeutic Window

Date: Monday 20th February | Time: 10.00-13.00

This workshop will share the latest science and lessons learned from preclinical development to **develop more clinically effective ADCs.**

The development path of ADCs is far more complex and challenging than for monoclonal antibodies. While many of the preclinical considerations for both are similar, special considerations must be taken into account when developing an ADC. Despite a plethora of in vitro assays and in vivo models to screen and evaluate ADCs, the challenge remains to improve preclinical ADC drug development that will be more predictive of clinical outcome.

Attend this discussion-led workshop to **improve your understanding of translational considerations for successful ADC development.**

Workshop leader
Donglu Zhang, Senior Scientist, **Genentech**

OR

Workshop C

Antibody Drug Conjugate Process Development & Formulation

Date: Monday 20th February | Time: 10.00-13.00

Focusing on preclinical toxicology supplies through to late phase manufacturing this workshop will distil experiences gained from the **process development, scale up and optimisation for ADC formulation**. It will also cover elements of cross-functional team collaboration to efficiently manufacture ADCs and how to liaise with CMOs for clinical drug product manufacture.

Attend this workshop to:

- Robustly scale up & optimise ADC process manufacturing for next generation ADCs
- Streamline timelines for ADC production by comprehensively managing internal cross-functional team collaboration
- Effectively work with and transfer ADC technology to external CMO

Workshop leader
Roberto Depaz, Senior Scientist, **MedImmune**

AND..

Workshop D

Design & Develop More Stable Site-Specific ADC Linker Chemistries

Date: Monday 20th February | Time: 14.00-17.00

The majority of ADCs currently in clinical development use only a limited number of chemical linkers. One of the major challenges in the advancement of safe and effective antibody-drug conjugates has been the development of **stable and specific chemical linkers between the cytotoxic drug and the monoclonal antibody**. While the synthesis of linker chemistry is quite complex and several aspects must be critically balanced to guarantee efficacy, ultimately, the nature of the chemical linker being used shapes the release profile of the cytotoxin.

This workshop will cover:

- How linker design is changing as the ADC field evolves
- Important considerations for designing the optimum linker
- Why have linkers failed to realise their potential?
- Different aspects of ADC conjugation chemistries from both biological and chemical perspectives

Workshop leaders

Jonas Helma, Ludwig-Maximilians-University of Munich

Dominik Schumacher, Leibniz-Institute for Molecular Pharmacology

OR

Workshop E

Intellectual Property Perspective on the Requirements for Successful ADC Drug Development

Date: Monday 20th February | Time: 14.00-17.00

Antibody-drug conjugates are highly complex entities that combine an antibody, a linker and a toxin. This complexity makes them demanding both technically and from a regulatory point of view, and difficult to deal with in their patent aspects. This workshop **discusses different issues of patent protection and freedom to operate with regard to this promising new class of drugs.**

Attend this workshop to:

- Navigate the IP maze related to ADCs
- Understand how technical issues of ADCs translate into the patent world
- Conquer the novelty/inventive step bars - moving targets
- Review considerations regarding freedom to operate

Workshop leader

Ulrich Storz, Senior Partner, Michalski Hüttermann Patent Attorneys

OR

Workshop F

Safely Handle Highly Potent Payloads & Manufacture ADCS

Date: Monday 20th February | Time: 14.00-17.00

Establishment and maintenance of measures to **ensure a safe workplace environment for developing hazardous ADC components** is imperative. Certain ADC payloads may turn out to be some of the most occupationally potent and toxic materials ever handled in drug development. This workshop will assess safety principles that have been honed over many years. Discussion will concentrate on both ADC R&D and manufacturing working environments.

Attend this workshop to learn about:

- The requirements for hazard assessments, as well as laboratory and manufacturing operations risk assessment
- Designing the most operative ADC manufacturing facility
- Navigating workplace testing
- Tools for systematic and effective ADC occupational health and safety management

Workshop leader

Justin Mason-Home, Managing Director, SafeBridge Consultants

Analytical & Bioanalytical Day | Monday 20th February 2017

Alain Beck, Senior Director, **Pierre Fabre**

9.00 Chair's Opening Remarks

Alex Lazar, Head, **ImmunoGen**

9.10 Considerations of Analytical Methods for ADCs

- Learn of several analytical tools and techniques for characterisation of ADCs and their components
- Improve screening and selection of most promising candidate to put forward
- Refer to ADC case studies for FDA and EMA expectations

9.40 Speed Networking

10.10 Morning Refreshments

Unique Mind Mapping Session

10.30 Think Tank Roundtable Sessions

More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas. A valuable chance for attendees to unite around hot topics and debate best practice. No more sitting quietly, this is a dedicated opportunity for you to voice your experiences and identify unique solutions.

11.30 Moderator Feedback & Audience Debate

More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas. A valuable chance for attendees to unite around hot topics and debate best practice. No more sitting quietly, this is a dedicated opportunity for you to voice your experiences and identify unique solutions.

12.00 Lunch & Networking

Technological Advancements in Analytics & Bioanalytics for ADCs

Yannis-Nicolas Francois, Assistant Professor, **University of Strasbourg**

13.00 Cutting-edge Capillary Electrophoresis – Mass Spectrometry Characterisation of Antibody Drug Conjugates

- Explore the benefits of advantages of utilising Capillary Electrophoresis – Mass Spectrometry, such as high resolution separation & miniaturised format
- Learn how to robustly characterise the size & charge variants of intact & reduced ADCs
- Explore in detail the challenges & the solutions of the last development of CE-MS methods for the characterisation of ADCs

Cong Wei, Senior Scientist, **Vertex Pharmaceuticals**

13.30 Unconjugated Payload Quantification & DAR Characterisation Of Antibody-Drug Conjugates Using High-Resolution MS

- Understand how high resolution MS may provide insight into ADC safety & efficacy
- Confidently determine unconjugated cytotoxic drug & DAR distribution in plasma
- Implement orthogonal acceleration quadrupole-time-of-flight MS

"All the presentations were relevant and very helpful. Thanks for making the conference so worthwhile"

Sanofi

14.00 **Spotlight Session Reserved for Equipment Provider**

- *More details to follow*

14.15 **Afternoon Refreshments & Networking**

Enhance Chances of Regulatory IND Success

Afsaneh Abdolzade-Bavil, Manager, **Biotest**

15.00 **Panel Discussion: Refine Industry-wide ADC Bioanalysis Strategy for Third Generation ADCs Coming Through the Pipeline**

- What analytes are normally assayed in screening stage?
- When the determination of DAR distribution in the ADC components in study samples needed?
- If LBA and LC/MS based assays both work, which one to choose and why?

This session will be a chaired panel interview in which experts from leading ADC bio-analytical companies will give their perspectives on how we are to overcome the challenges of coming to an industry wide ADC bioanalytical development consensus

Alain Beck, Senior Director, **Pierre Fabre**

15.30 **Chair's Closing Remarks**

> "A thoroughly engaging and intellectually stimulating experience, World ADC has been packed with new ideas, techniques & friends. The possibilities for new breakthroughs and collaborations based on my time here has made it even more motivating to get back to the lab"
>
> **The Scripps Research Institute**

> "Excellent structure, great scientific talks and discussion"
>
> **Novartis**

Conference Day One | Tuesday 21st February 2017

Alain Beck, Senior Director, **Pierre Fabre**

8.50 Chair's Opening Remarks

John Lambert, Executive Vice President & Distinguished Research Fellow, **ImmunoGen**

9.00 Preclinical & Translation of IMGN632 & Clinical Update of Mirvetuximab Soravtansine

- Review the preclinical & translational development of IMGN632, a CD123-targeting antibody with a potent DNA-Alkylator payload
- Mirvetuximab soravtansine (IMGN853) targets folate receptor alpha (FRĐ), a target highly expressed in the majority of cases of epithelial ovarian cancer
- Review early phase clinical studies, which show that the ADC is active at well tolerated doses & suggests that FRĐ expression is an important consideration for response
- Mirvetuximab soravtansine is now in phase III clinical trial in FRĐ-positive, platinum-resistant epithelial ovarian cancer

Puja Sapra, Executive Director, **Pfizer**

9.30 The Next ADC Breakthrough Therapy – A Case Study of Inotuzumab Ozogamicin

- Gain lessons learned from the development of Mylotarg & Inotozumab Ozogamicin
- Review the journey over the last two decades on DNA damaging agents
- Explore the next generation of Pfizer DNA damaging ADCs

10.00 Speed Networking

This session is a great opportunity to introduce yourself to the attendees that you would like to have more in depth conversations with. This is the ideal opportunity to get face-to-face time with many of the brightest minds working in the ADC field & establish meaningful business relationships.

10.30 Morning Refreshments

Discovery Stream

Chair: Kurt Gish, Associate Director II, **AbbVie**

Explore Next Generation Linker & Payload Chemistries

11.00 **Evaluation of Peptide Linked Maytansinoid ADCs That Release Mono-Charged Metabolites**

- Comparison of ADCs that release mono-charged metabolites to ADCs that utilise non-cleavable linkers, which typically release zwiterionic metabolites
- Identification of peptide linkages that can or can not be cleaved in pre-lysosomal compartments & the impact this has on an ADCs cytotoxicity
- MTD & clearance rate, in mice, of the lead peptide linked maytansinoid ADC

Wayne Widdison, Associate Director, **ImmunoGen**

Development Stream

Chair: Anette Sommer, Principal Scientist, **Bayer**

Robustly Characterise ADC Programmes & Improve Preclinical Development

11.00 **Application of High Resolution Mass Spectrometry for the Quantitative Analysis of Intact IgG & ADC in Biological Fluids**

- Discover advancements in high resolution mass spectrometry for ADC drug development
- Learn how to effectively implement high resolution mass spectrometry to quantify ADC in biological fluid
- Interpret high resolution data to better inform preclinical development of ADC candidate

Olivier Heudi, Laboratory Head, **Novartis**

Manufacturing Stream

Chair: Pernille Hemmingsen, Project Manager, **Genmab**

Process Quality Control & Final Product Characterisation

11.00 **Analytical Characterisation of Antibody-drug Conjugates: Strategy, Methodology & Case Study**

- Explore recent developments & future trends in the characterisation of ADCs using MS
- Implement a robust methodology & processes to ensure robust quality control of final product characterisation
- Case study of analytical characterisation of next generation ADC

Guodong Chen, Senior Principal Scientist, **Bristol-Myers Squibb**

11.30 **Warheads for Targeted Therapies of Cancer: The Concept of pro-PBDs & Strategies for Their Conjugate Design**

- PBDs & their dimers bis-PBDs are too toxic to be used as antineoplastic agents; instead, they are excellent candidates for the design of ligand-drug conjugates for cancer targeting
- Listen to this talk to learn how to overcome undesired interactions of conjugated PBDs in a living system
- Explore Endocyte's new concept for design of *pro*-PBDs
- Learn strategies for efficient total synthesis of *pro*-PBDs & their further conjugation

Iontcho Vlahov, Vice President, **Endocyte**

11.30 **Mass Spectrometry Toolkit for the Characterisation of ADCs**

- Determination of DAR for Lys & Cys-linked ADCs by 1D & 2D-LC/MS
- Determination of conjugation sites & site occupancy using a peptide mapping methodology with MS detection & ETD fragmentation
- Application of the methods to Kadcyla® & Adcetris®

Arnaud Delobel, Scientific Manager, **Quality Assistance**

11.30 **Real-time Monitoring of Conjugation Processes: PAT as a Conjugation Process Development Tool & Potential Control Strategy Element**

- Key components of a PAT system for conjugation processes
- Leveraging PAT for conjugation process development & characterisation
- PAT versus grab-sampling as strategies for in-process control
- Looking forward: the leap from monitoring to control & automation

Damon Meyer, Principal Scientist, **Seattle Genetics**

12.00 **A Novel Linker to Enable Alcohol-Containing Payloads for the Preparation of Antibody-Drug Conjugates**

- Explore the development of a new linker chemistry; the methylene-alkoxy-carbamate (MAC), which enables direct conjugation of drugs through alcohol functional groups
- Such groups are present on a diverse array of synthetic drugs & cytotoxic natural products, expanding the potential chemical space available for payload selection
- As proof-of-concept, we have linked Auristatin E through the secondary alcohol of the norephedrine residue & characterised the stability & *in vivo* activity of the resulting ADCs
- Learn how this novel linker chemistry is currently being applied to new payloads that were inaccessible with previous technology

Robert Kolakowski, Senior Scientist, **Seattle Genetics**

12.00 **Intratumor Catabolites can Predict ADC Efficacy**

- Review of key parameters that may drive ADC efficacy & toxicity
- Catabolite release & retention from ADCs
- Case studies of intratumor catabolite concentration - ADC efficacy correlation
- Implications in preclinical ADC discovery & potential clinical outcomes

Donglu Zhang, Principal Scientist, **Genentech**

12.00 **Challenges in ADC Manufacturing, from Conjugation to Fill-Finish**

- *More details to follow*

Maria Elena Guadagno, Director, **BSP Pharmaceuticals**

12.30 **Lunch & Networking**

Design & Synthesise Warheads with Novel Mechanisms of Action

13.30 **Site-Specific Conjugation of Single & Dual Warheads to Antibodies**

- Develop site-specific antibody conjugation technologies based on natural lysine & engineered selenocysteine residues
- Apply these site-specific antibody conjugation technologies to the generation of dual warhead ADCs
- Explore virtues & shortcomings of single versus dual warhead ADCs in *in vitro* & *in vivo* models of cancer

Christoph Rader, Associate Professor, **The Scripps Institute**

Practical Lessons Learned from Preclinical ADC Development

13.30 **Relevant Concentrations of Antibodies in Individual Tissues**

- Discover new knowledge & data gathered around tissue distribution of monoclonal antibodies
- Biodistribution data & newly measured physiological parameter values emphasize the importance of accurate residual plasma corrections to correctly predict interstitial tissue concentrations
- Learn how to integrate biodistribution data in a physiologically based pharmacokinetic model to better predict the pharmacokinetics for various doses & dosing schedules

Miro Eigemann, Researcher, **Roche**

Develop Scalable, Reproducible & Safe Processes

13.30 **Develop Scalable, Reproducible & Safe Processes**

- Process development & scale-up of ADCs
- Gain early knowledge on Critical Quality attributes
- Contribution of process understanding on the justification of specifications

Joachim Krueger, Head, **Bayer**

14.00 **Development of Homogenous Next Generation ADCs Using Enzymatic Conjugation**

- *More details to follow*

Ulf Grawunder, CEO & Founder, **NBE Therapeutics**

14.00 **Mechanisms of Resistance to T-DM1 in Preclinical Models**

- Resistance to T-DM1 is not associated with broad resistance to other therapies
- The microtubule network is modified in T-DM1 resistant cells
- T-DM1 resistant cells display a variety of molecular alterations

Charles Dumontet, Team Leader, **Cancer Research Centre Lyon**

14.00 **Learn of Tools which Manage Conjugation Process & Act as Robust Control**

- *More details to follow*

Roberto Depaz, Senior Scientist, **MedImmune**

14.30 **Determination of Antibody-Drug Conjugate Released Payload Species Using Directed *in vitro* Assays & Mass Spectrometric Interrogation**

- Explore the development of an *in vitro* method for the identification of payload species released from ADCs in the presence of lysosomal enzymes
- This method utilises commercially available human liver S9 fraction as the source of these enzymes & this has certain advantages over lysosomal fractions or purified enzymes
- Evaluate the characterisation & performance of this assay with multiple ADCs composed of known & novel linkers & payloads
- Review as observation of incomplete degradation of mAb protein chains by lysosomal enzymes *in vitro*, believed to be the first report of this phenomenon involving an ADC therapeutic

Chakrapani Subramanyam, Associate Research Fellow, **Pfizer**

14.30 **Rapid Quantification of a Cleavable Antibody-Conjugated Drug by Liquid Chromatography/Tandem Mass Spectrometry with Microwave-Assisted Enzymatic Cleavage**

- Explore the development of a novel bioanalytical method for the quantification of a cleavable antibody-conjugated drug in plasma
- Significantly improve throughput by combining a microwave-assisted, enzymatic cleavage of conjugated drugs from ADCs with a 96-well based sample preparation procedure to immunocapture ADCs in plasma
- The released drug is subsequently quantified using a LC/MS/MS method.
- Develop a novel method for high-throughput, generic, & sensitive quantification of antibody-conjugated microtubule inhibitors (such as MMAE) for preclinical PK/PD studies
- Effectively measure the level of conjugated drug in a preclinical PK/PD study in mice

Ling Xu, Senior Scientist, **Takeda**

14.30 **Learn of Tools which Manage Conjugation Process & Act as Robust Control**

- Developing robust antibody-drug conjugate processes requires a fundamental understanding of the mechanism of conjugation, reaction kinetics & chemical stability
- Explore learnings from site specific conjugation process
- Case studies & considerations for clinical manufacturing development

Tony Cano, Senior Director, **Stemcentrx-AbbVie**

15.00 **Afternoon Refreshments & Networking**

Develop Next Generation Antibody-Drug Conjugates

Alain Beck, Senior Director, **Pierre-Fabre**

16.00 **Cutting-Edge Analytical & Structural Methods for Characterisation of ADCs**

- *More details to follow*

Kurt Gish, Associate Director II, **AbbVie**

16.30 **Preclinical Evaluation Of ABBV-838, A First-In-Class Anti-CS1 Antibody-Drug Conjugate for the Treatment of Multiple Myeloma**

- Potent tumour growth inhibition, including regressions & cures, was observed in multiple xenograft models of myeloma following a single dose of ABBV-838
- In preclinical xenograft models, ABBV-838 enhanced the anti-tumour efficacy when combined with pomalidomide or bortezomib, compared to that seen with either agent alone
- An additional process step was added to enrich for those antibodies containing primarily 2 molecules of MMAE
- This "E2" format was able to deliver more conjugated MMAE in preclinical safety studies than a "DAR4" format & had equal or better efficacy when normalised by conjugated MMAE dose
- ABBV-838 is currently being investigated in a Phase 1 first-in-human safety study

Scientific Poster Session & Networking

After the formal presentations have finished, the learning and networking carries on. The Poster Session is an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. During this session over 25 scientific posters will be presented from novel linker designs to validation of site specific conjugation technologies and more informative *in vivo* models.

Conference Day Two | Wednesday 22nd February 2017

Alain Beck, Senior Director, **Pierre-Fabre**

8.50 Chair's Opening Remarks

Gary Chen, President, **Concortis Biotherapeutics**

9.00 Preclinical Development of Superior ADCs Incorporating Novel Linker & Warhead Designs

- Robustness of screening panel from antibody to ADC leads in 2 months, from target IND within 2 years
- Preclinical studies of several ADCs showing superior PK, PD & toxicity profiles
- Promise of multifunctional ADCs

Ron Lin, Founder & CEO, **AbGenomics**

9.30 AbGn-107, an ADC Targets Gastrointestinal Tumours

- Characterisation of the expression profile of targeting antigen – a glyco-epitope observed mainly on GI tumour cells
- Pre-clinical efficacy in several xenograft tumour models
- Toxicity studies in rodent & non-human primates & the determination of first human dose

TBC **Millipore Sigma**

10.00 Platform Approach to ADC Production: Integrating Bio-Process Development, Engineering & Manufacturing

- Efficiencies associated with bio-process, engineering & manufacturing collaboration
- Portability of platform approach across conjugation technologies
- Application of single use technologies

10.30 More Refreshments & Networking

Discovery Stream

Chair: Kurt Gish, Associate Director II, **AbbVie**

Minimise ADC Toxicity Through Antibody Engineering & Novel Targets

11.30 **Design & Development of a Non-Internalising ADC Product**

- Development of F16-based ADCs: antibody format: IgG vs SIP; linker design & optimisation
- Improve understanding of the importance of the payload on ADC activity
- Small molecule drug conjugates (SMDCs) as a possible alternative to ADCs

Martin Mattarella, Head, **Philochem**

Development Stream

Chair: Anette Sommer, Principal Scientist, **Bayer**

Successfully Translate into the Clinic

11.30 **Development of a HER2 Bispecific Antibody-Drug Conjugate in Breast & Gastric Cancers**

- Update on development of a HER2 bispecific ADC with data supporting treatment of specific patient populations
- Discuss selection of ADC targets in specific tumour types
- Describe criteria for selecting antigens for ADC
- Overview of ADC programs in development at MedImmune

Steve Coats, Vice President, **MedImmune**

Manufacturing Stream

Chair: Pernille Hemmingsen, Project Manager, **Genmab**

Effectively Outsourcing ADC Manufacturing & Managing Complex Supply Chains

11.30 **Robustly Outsource & Transfer ADC Technology**

- Overcome challenges of process development, optimisation, scale-up & technical transfer
- Review lessons learned for robust GMP manufacturing
- Understand how to work effectively with chosen CMOs for Process Development or Manufacturing
- Managing internal and external development and manufacturing capabilities

Olivier Marcq, Group Lead, **Agensys**

12.00 **Discovery of Four Novel Protein Domains Developed from an IgG-binding Domain of Streptococcal Protein G & Protein A**

- Discovery of four novel protein domains developed from an IgG-binding domain of Streptococcal Protein G
- Domains show obligate Fab binding & can be used for site-specific & covalent attachment exclusively to the constant part of the Fab fragment of an antibody
- The two different domains can covalently label IgG of mouse & human
- Demonstrate functionality in both an ELISA & in an NK-cell antibody-dependent cellular cytotoxicity assay
- Novel tools for controlled labelling of Fab fragments & full-length IgG

Sophia Hober, Professor, **KTH**

12.00 **MM-302: Developing the Next Generation of Alternative Formats to ADCs**

- MM-302 is novel HER2-targeted liposomal doxorubicin
- Explore alternative formats to antibody's for an improved efficacy & safety profile
- Review recent Phase I & Phase II clinical data for MM-302

Thomas Wickham, Vice President, **Merrimack Pharmaceuticals**

12.00 **Utilise Disposable Technologies for ADC Manufacturing**

- Understand how single use technologies can reduce upfront capital costs of establishing manufacturing processes & requirement for utilities such as clean-in-place reagents, water for injections & clean steam for equipment sterilisation
- Discuss the advantages of disposable technologies with design flexibility during development & scale-up
- Lessons learned from inotuzumab ozogamicin

Tok Han, Director/TL, **Pfizer**

12.30 **Identification & Validation of LAMP1 as a Suitable Target for an ADC Approach**

- Target identification process based on immunisation by PDX & IHC screening
- Target validation by transversal & complementary assays
- Focus on SAR428926, an anti-LAMP1-SPDB-DM4 ADC

Yves Baudat, Scientist, **Sanofi**

12.30 **A Phase I Study of PF-06647020, an Antibody-Drug Conjugate (ADC) Targeting Protein Kinase 7 (PTK7), in Patients with Advanced Solid Tumours**

- *More details to follow*

Robert Xin, Executive Director & Global Clinical Lead, **Pfizer**

12.30 **Improve Batch-to-Batch Reproducibility During ADC Manufacturing**

- Ensure batch-to-batch reproducibility of ADCs during process development & final product analysis
- Maintain robust processes during manufacturing scale up
- Work with technology transfer teams & CMO to replicate when outsourced

Judy Hsii, Senior Engineer & Group Leader, **Genentech**

13.00 Lunch & Networking

Approaches for Maximising Therapeutic Index & Improving ADC Candidates

Dhaval Shah, Assistant Professor, **University of Buffalo**

14.00 Quantitative Characterisation of the Bystander Effect of ADCs

- Understand how the different amount of antigen +ve cells in a co-culture system affects the bystander effect of ADC
- *In vivo* PK data in tumour bearing mice will also be presented to show how the presence of antigen +ve cells affect the tumour concentrations of unconjugated drug
- A novel mathematical model will be presented that can help evaluate the effect of different determinants on the bystander effect of an ADC *in silico*

David Satijn, Director, **Genmab**

14.30 Elimination of Multidrug-Resistant Melanoma by HuMax-AXL MMAE

- AXL is overexpressed in many types of cancer, including melanoma & is associated with EMT & increased invasiveness of tumours.
- AXL is also up regulated upon resistance to a variety of therapies including the oft-used BRAF & MEK inhibitors in melanoma
- HuMax-AXL-MMAE shows efficacy in AXL-expressing melanoma CDX & PDX models

15.00 Afternoon Refreshments & Networking

Lucia D'Amico, University Hospital Basel

16.00 Improve Understanding of Contributions of ADCs with Immune Checkpoint Modulators

- *More details to follow*

Christine Sedlik, Researcher, **Institut Curie**

16.30 Effective Antitumor Therapy Based on a Novel Antibody-Drug Conjugate Targeting The Tn Carbohydrate Antigen

- Discover the potential of Chi-Tn, a mAb directed to a glyco-peptidic tumor-associated antigen, to be used as an ADC for cancer treatment
- Explore flow cytometry and deconvolution microscopy data which demonstrates rapid internalisation
- Develop next generation ADCs - Chi-Tn mAb conjugated to auristatin F exhibits efficient antitumor activity *in vivo*

Alain Beck, Senior Director, **Pierre-Fabre**

17.00 Chair's Closing Remarks

"Well organised, great list of speakers, nice variety of activities. Perfect size to meet everyone and feel comfortable engaging others"

Novartis

"Yet another 'grand slam' of a conference"

Igenica

Networking Opportunities

Networking at World ADC Berlin will be one of the key highlights of the summit for you.

With **more ADC experts in attendance than any other meeting in Europe, this is your best opportunity to interact with your industry peers.**

Connect with over 300 attendees during each networking session. Engage in debate during the Poster Session. Mingle with your peers at the pre-conference Partner and Investor Evening.

World ADC Berlin will bring you real connections, tangible results and future business.

You'll Meet People From...

Seniority*



Demographics



*Data correct from 2011-2016

Scientific Poster Session

Share your research with pioneers of the ADC field

Disseminate your findings to the community and **gain feedback on your latest research**.

Open to all, the Scientific Poster Session is one of the most popular sessions at World ADC.

Taking place after the first day of presentations and learning this data rich session is an invaluable opportunity for you to **review 25+ scientific posters as well as present your own research**.

All posters are subject to approval by the organisers.

Please send your abstract to adc@hansonwade.com by **Thursday 2nd February** to be eligible.

"World ADC meeting was very beneficial for people who are new to the field as well as for experts"

Bristol-Myers Squibb

300+ attendees
120+ companies in attendance
12+ hours of networking

Snapshot of Companies Who Attend World ADC

abbvie, ADC Therapeutics, Agensys, Amgen, AstraZeneca, Biotest, Celldex, Concortis, CytomX Therapeutics, Endocyte, Merck, Millennium, Novartis, Pfizer, Roche, Seattle Genetics, Sprogen, Stemcentrx, Sutro Biopharma, Synthon

Tel: +44 (0)203 141 8700 **Email:** adc@hansonwade.com
www.worldadc-europe.com @World_ADC #WorldADC Antibody Drug Conjugates

hansonwade love what you do

World ADC Partners

Senior Partners

Partners

Exhibitors

Partnering with World ADC Berlin

Partnering with World ADC is an opportunity to **elevate your company's standing** and **influence industry thinking** in the ADC community. Your brand, your message, your reputation, showcased in front of **300+ leading European ADC developers.**

This could involve presenting on the agenda, hosting networking sessions, exhibiting, or brand exposure. But our focus and reach is much wider. From being fully integrated across a multi channel global communication strategy, to targeted introductions to the right individuals in your target market, we have opportunities that offer it all.

Greater brand awareness, nurtured lead generation and networking of surgical precision.

Contact us today at adc@hansonwade.com to find out how we can help you achieve your business goals faster.

"World ADC provides a unique environment to immerse into the ADC world and network with the key players in the space"

Research Corporation Technologies

Pricing

Register

www.worldadc-europe.com/attend/register/
Tel: +44 (0)203 141 8700
Email: adc@hansonwade.com
Mail:
Hanson Wade
4th Floor, 52 Grosvenor Gardens,
London, SW1W 0AU

Team Discounts

- **10% discount –** 3 delegates
- **15% discount –** 4 delegates
- **20% discount –** 5 or more

Please note that discounts are only valid when 3 or more delegates from one company book at the same time

Top 3 Benefits of Attending

1. Immerse yourself in cutting-edge ADC science and hear the latest data, insight and lessons learned to power the development of your lead candidate
2. Covering every element of ADC discovery, development, manufacturing and clinical programs this summit offers you an unrivalled breadth of content
3. Unparalleled opportunity to catch-up with over 300 of your ADC colleagues and foster new industry connections

"Great conference with broad coverage on the developments in the field. A must meeting to attend"

Glykos

	Register & Pay before 4th Nov	Register & Pay before 2nd Dec	Register & Pay before 13th Jan	Standard Prices
Gold Conference + 2 workshops or Analytical & Bioanalytical Day	€3197 **(save €500)**	€3297 **(save €400)**	€3397 **(save €300)**	€3497 **(save €200)**
Silver Conference + 1 workshop	€2698 **(save €400)**	€2798 **(save €300)**	€2898 **(save €200)**	€2998 **(save €100)**
Bronze Conference only	€2199 **(save €300)**	€2299 **(save €200)**	€2399 **(save €100)**	€2499
Analytical & Bioanalytical Day	€1198			
Workshop	€699			

* Does not include VAT at 19%

Venue

Maritim proArte Hotel Berlin
Freidrichstrasse 151
10117 Berlin
Germany

https://www.maritim.de/de/hotels/deutschland/proarte-hotel-berlin/uebersicht

"World ADC is the largest conference with an exclusive focus on ADC. It is an excellent chance to assess the field's direction and meet with other ADC companies"

Tanabe Research Laboratories

Code: 0000